Q2 2023
Released Aug 1, 2023, before the open
10-Q filed Aug 9, 2023, 38 days after period end · 0000078003-23-000088
Q2 2023 · 10-Q
Revenue$13.01B$13.01B −53.1% vs Q2 2022−29.6% vs Q1 2023
Net Income$2.33B$2.33B −76.5% vs Q2 2022−58.0% vs Q1 2023
EPS Diluted$0.41$0.41 −76.3% vs Q2 2022−57.7% vs Q1 2023
Operating Cash Flowderived-$1,208,000,000N/M
Free Cash Flowderived-$2,122,000,000N/M
Margins · derived
Net margin17.9%−17.8 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $13.01B | $27.74B | $18.90B | $9.86B |
| Net Income | $2.33B | $9.91B | $5.56B | $3.49B |
| EPS Diluted | $0.41 | $1.73 | $0.98 | $0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR